PIA
LXRX icon

Piedmont Investment Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Piedmont Investment Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-750
Closed -$9K – 1740
2018
Q2 		$9K Buy
+750
New +$7.67K ﹤0.01% 1869

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SGA
Sector Gamma AS Oslo, Norway $423M AUM 17.56% 1-Year Est. Return

Piedmont Investment Advisors's LXRX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2018, closing a stake of 750 shares — an estimated $9K sold.

Piedmont Investment Advisors first reported a position in LXRX in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 119 funds tracked by Wall St. Rank hold LXRX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Lexicon Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 750 Lexicon Pharmaceuticals shares in Q3 2018, an estimated $9K.
  • Piedmont Investment Advisors first reported a position in Lexicon Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Lexicon Pharmaceuticals position peaked at $9K in Q2 2018.
  • 119 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.